A Standardized In Vitro Framework for Evaluating Hair Care Products: Hair Parameters and Efficacy Performance

Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

Microneedling for hair restoration involves daily use of a 0.3 mm device and weekly use of a 0.5 mm device. Combining microneedling with Minoxidil can enhance hair growth.

DHT promotes beard growth but causes scalp hair loss due to inflammation and fibrosis. Treatments like finasteride and minoxidil help with hormonal signals and blood flow but don't address underlying inflammation.

Before starting hair loss treatment, it's suggested to undergo various blood and health tests to minimize side effects. The checklist includes tests for kidney function, liver enzymes, blood sugar, vitamins, hormones, and more.

The user has been experiencing hair loss despite using finasteride and dutasteride, with recent photos showing significant thinning. They are considering increasing their dutasteride dosage and possibly trying microneedling, while also addressing concerns about diet and nutrient deficiencies.